Jeffrey B. Kopp, M.D.

Senior Investigator

Kidney Diseases Branch

NIDDK

Building 10, Room 3N116
10 Center Drive
Bethesda, MD 20814

301-594-3403

jeffreyk@mail.nih.gov

Research Topics

Current Research

Dr. Kopp leads a translational research group within the Kidney Disease Section, Kidney Diseases Branch, studying focal segmental glomerulosclerosis (FSGS) and related podocyte diseases.

Recent highlights

  • Chromosome 22 harbors a major risk locus for kidney disease in African Americans, including FSGS, HIV-associated nephropathy, and arterionephrosclerosis (hypertension-attributed kidney disease).  APOL1 coding variants, which protect against trypanosomal infection, are strongly associated with kidney disease (odds ratios 7-29).  The mechanism of glomerular injury is unknown.
  • The HIV-1 protein Vpr, expressed in the glomerular podocytes, is sufficient to reproduce the chief features of HIV-associated collapsing glomerulopathy in transgenic mice.

Current research efforts

  • determining the mechanisms by which Apol1 variants damage the glomerulus
  • examining whether cardiotrophin-like cytokine 1 is a permeability factor that contributes to recurrent FSGS following kidney transplant
  • an open label phase II trial examining the efficacy of rituximab combined with cyclosporine (for 48 weeks) for treatment of refractory podocyte disease
  • participating in the ORD-funded NEPTUNE study of nephrotic diseases

Information for patients

  • We are actively recruiting individuals with focal segmental glomerulosclerosis and those with undiagnosed nephrotic syndrome or proteinuria.
  • All NIH trials are listed at clinicaltrials.gov.
  • Information about glomerular diseases is available on the Glomerular Disease Primer page​.

Reagents available to the research community

Transgenic mice

  • Podocin promoter/rTTA (reverse tetracycline transactivator)—also available from JAX and as herozygotes or homozygotes
  • TRE (tet responsive element)/Vpr
  • Alb/TGF-beta mice (request permission from Dr. Snorri Thorgeirsson, NCI)

Antibodies

  • rabbit polyclonal antibody to Vpr1-50 peptide—also available from AIDS Research and Reference Reagent Program
  • rabbit antiserum to human podocin (cross-reactive with mouse podocin)
  • rabbit antiserum to human nephrin (no cross-reactivity with mouse nephrin)
  • goat antimouse mesangial cell serum, for induction of glomerulonephritis in mice

Podocyte cell lines

  • mouse podocytes, immortalized with thermosensitive SV40 T Ag and bearing podocin/rtTA, for expression of genes of interest in cultured mouse podocytes
  • same, plus TRE silencer to reduce background expression
  • human urine derived podocyte-like epithelial cells (HUPECs), immortalized with hTERT and thermosensitive SV40 T Ag

Please contact us for further details.  NIDDK MTAs are available through Technology Advancement and Transfer.​

Biography

  • Consulting Nephrologist, Mark Hatfield Clinical Research Center, NIH, Present
  • Commissioned Officer (Captain) Active Member (Rapid Deployment Force Teams PHS 1), U.S. Public Health Service, Present
  • Adjunct Professor of Medicine, Uniformed Services University of the Health Sciences, Present
  • Senior Investigator, NIDDK, NIH, 1995-present
  • Medical Staff Fellow, NIH, 1987-1995
  • Complete Training in Internal Medicine and Nephrology, University of Washington, 1987
  • M.D., University of Pennsylvania Medical School, 1980
  • B.A., Harvard College, 1975

Selected Publications

  1. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB, SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83(1):114-20.

  2. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-37.

  3. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175-84.

  4. Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008;22(2):234-47.

  5. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(5):906-13.


This page was last updated on April 13th, 2017